| Literature DB >> 28811851 |
Saeeda Fatima1, Benajmin Dao1, Ayesha Jameel1, Konika Sharma1, David Strogatz2, Melissa Scribani2, Harish Raj Seetha Rammohan3,4.
Abstract
BACKGROUND: The epidemiology of infective endocarditis (IE) depends on a number of host factors whose prevalence can vary globally. The usual patient population affected by IE is sicker and older, often with many comorbid conditions. The risk is growing in younger populations due to the emerging epidemic of intravenous (IV) drug use. We have performed a temporal trend analysis of various factors of IE in the rural counties covering a major part of central Upstate New York.Entities:
Keywords: Epidemiology; Infective endocarditis; Intravenous drug use
Year: 2017 PMID: 28811851 PMCID: PMC5544479 DOI: 10.14740/jocmr3131w
Source DB: PubMed Journal: J Clin Med Res ISSN: 1918-3003
Figure 1Total incidence of IE from 2011 to 2016.
Figure 2Incidence of IE in population 18 years and older from 2011 to 2016.
Figure 3Incidence of IE in population 65 years and older from 2011 to 2016.
Incidence of IE From 2011 to 2016 in IV Drug Users
| Year of admission | Number of cases diagnosed with IE | Number of cases with reported IV drug use | Percentage (%) of cases using IV drugs |
|---|---|---|---|
| 2011 | 6 | 1 | 16.7 |
| 2012 | 5 | 1 | 20 |
| 2013 | 9 | 1 | 11.1 |
| 2014 | 8 | 0 | 0 |
| 2015 | 14 | 6 | 42.9 |
| 2016 | 12 | 4 | 33.3 |
Characteristics of Patients
| Variables | IE, 2011 - 2016, n = 54 |
|---|---|
| Demographics | |
| Age, median years (range) | 61.5 (21 - 93) |
| Female gender | 19 (35%) |
| Race (Caucasian) | 54 (100%) |
| Diagnosis | |
| Definite IE | 45 (85%) |
| Possible IE | 9 (14%) |
| Comorbidities | |
| Diabetes mellitus | 21 (38.8%) |
| HIV | 1 (1.85%) |
| Neoplasm | 6 (11.1%) |
| Other immunosuppressed states | 2 (3.7%) |
| Valvular heart disease | 15 (28.8%) |
| Heart failure | 11 (20.4%) |
| Bicuspid aortic valve | 1 (1.85%) |
| Atrial fibrillation | 13 (24.07%) |
| Distant infections | 12 (22.2%) |
| Pulmonary disease | 11 (20.37%) |
| Renal insufficiency | 13 (24.1%) |
| Dialysis dependent | 7 (12.9%) |
| Predisposing factor | |
| Rheumatic heart disease | 1 (1.85%) |
| Mitral valve prolapse | 0 |
| IV drug use | 13 (24.1%) |
| Previous cardiac surgery | 16 (29.6%) |
| Congenital heart disease | 1 (2.38 %) |
| Previous IE | 12 (22.2%) |
| Implantable intra-cardiac device | 8 (14.8%) |
| Central venous line | 6 (11.1%) |
| Affected valve | |
| Native valve | 39 (72.2%) |
| Prosthetic valve | 7 (12.9%) |
| Lead infection | 8 (14.8%) |
| Aortic | 12 (22.2%) |
| Mitral | 26 (48%) |
| Tricuspid | 7 (12.9%) |
| Pulmonary | 3 (5.5%) |
| Site of acquisition | |
| Community acquired | 43 (79.6%) |
| Nosocomial | 2 (3.7%) |
| Healthcare associated | 9 (16.7%) |
| Causative organism | |
| | 21 (38.3%) |
| MSSA | 14 (66.6%) |
| MRSA | 7 (33.3%) |
| Coagulase negative Staph | 6 (11%) |
| Streptococcus species | 9 (16.6%) |
| Enterococcus | 9(16.6%) |
| Culture negative | 6 (11%) |
| Others | 3 (5.5%) |
| Outcomes | |
| Median length of stay | 11 |
| In-hospital death | 3 (5.5%) |
| 6-month mortality | 5 (9.2%) |
| Valve surgery indicated (within 6 weeks) | 15 (27.7%) |
| Valve surgery indicated (6 week to 1 year) | 3 (5.5%) |
| Valve surgery performed (within 6 weeks) | 8 (14.8%) |
| Valve surgery performed (6 week to 1 year) | 4 (7.4%) |